The company hopes to replicate its early data in future studies, making a case that better early diagnosis can improve outcomes for patients with schizophrenia and bipolar disorder.
By Justin Petrone Longtime array rivals Affymetrix and Illumina last week introduced new chips targeting the exome, exonic variants in the protein-coding regions of the human genome.
Researchers Combine Metabolism and Transcriptional Profiling to Predict Poor Breast Cancer Outcome
The researchers found that treatment with lactate and ketones causes cancer cells to express gene profiles associated with “stemness.” They believe that these gene signatures could, in turn, predict poor clinical outcome in breast cancer patients.
The new arrays, scheduled to launch later this month, will enable researchers to examine alternately expressed exons, and are in line with Agilent's effort to build its portfolio in the gene expression market.